Verberk, Inge M. W. http://orcid.org/0000-0003-0341-7445
Thijssen, Elisabeth
Koelewijn, Jannet
Mauroo, Kimberley
Vanbrabant, Jeroen
de Wilde, Arno
Zwan, Marissa D.
Verfaillie, Sander C. J.
Ossenkoppele, Rik
Barkhof, Frederik
van Berckel, Bart N. M.
Scheltens, Philip
van der Flier, Wiesje M.
Stoops, Erik
Vanderstichele, Hugo M.
Teunissen, Charlotte E.
Funding for this research was provided by:
Alzheimer Nederland (NL-17004)
Health˜Holland (LSHl17OO1)
NCDC, Deltaplan Dementie, ZonMW Memorabel (73305095005)
Article History
Received: 8 June 2020
Accepted: 10 September 2020
First Online: 28 September 2020
Ethics approval and consent to participate
: Research was approved by the medical ethical committee of the VU University medical center and was in accordance with the Helsinki Declaration of 1975. All subjects provided written informed consent to use their medical data and biomaterials for scientific research.
: Not applicable.
: IV, ET, JK, AdW, MZ, SV, RO, BvB, and WvdF report no financial disclosures or conflicts of interest. KM, JV, and ES are employees of ADx Neurosciences NV and report no financial disclosures or conflicts of interest. HV is a co-founder of ADx NeuroSciences NV and a founder of Biomarkable bvba. FB has received consultancy fees from Roche, Biogen, Merck, IXICO, Bayer, and Novartis. PS has received consultancy/speaker fees (paid to the institution) from Biogen, People Bio, Roche (Diagnostics), Novartis Cardiology. He is PI of studies with Probiodrug, EIP Pharma, IONIS, CogRx, AC Immune, and Toyama. CT has a collaboration contract with ADx Neurosciences, performed contract research or received grants from Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, Roche.